kezar life sciences share price

Kezar Life Sciencess next ex-dividend date is July 28 2022. Kezar Life Sciences Inc is a clinical-stage biotechnology company.

Kezar Kzr Doubles On Promising Kidney Disorder Study Data

Start price Target price Perf.

. Kezar Life Sciences John Fowler is our Co-Founder Chief Executive Officer and a member of the board of directors bringing over 20 years of executive leadership experience to the company. Jun 30 Price target increased to US1967 Up from US1833 the current price target is an average from 5 analysts. Free Cash Flow per Share - - - - -.

It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. Stock is up 52 over the past year. Shares Out 6042M 10 Day Average Volume 073M Dividend - Dividend Yield - Beta 010 YTD Change -4055 RATIOSPROFITABILITY EPS TTM -105 PE TTM -951 Fwd PE.

Most recently he served as Head of Corporate Development Inflammation and Fibrosis at Gilead Sciences. View Kezar Life Sciences stock share price financial statements key ratios and more at Craft. Get the latest Kezar Life Sciences Inc KZR detailed stock quotes.

Prior to co-founding Kezar between 2009 and 2014 John co-founded and was CEO of HealthCPA a provider of patient advocacy and insurance navigation services. Latest Kezar Life Sciences Inc KZRNSQ share price with interactive charts historical prices comparative analysis forecasts. These unique approaches are designed to inhibit multiple drivers of disease resulting in a potentially broad treatment effect against a range of chronic conditions.

Is a clinical-stage biopharmaceutical company that is focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Join the sharewise community. Kezar Life Sciences Inc NASDAQ.

Get the latest Kezar Life Sciences Inc KZR real-time quote historical performance charts and other financial information to help you make more informed trading and investment decisions. Maintained a Buy rating on the stock and raised its price target from 20 to 22. Kezar Life Sciences share price went up by 7197 last month.

Key Stock Data PE Ratio TTM NA EPS TTM -105 Market Cap 31899 M Shares Outstanding 6042 M. Stock prices are provided by BSB-Software. Stopped prediction by IfYouCanDreamItYouCanDoIt for Kezar Life Sciences.

New target price is 138 above last closing price of US827. Kezar Life Sciences GAAP EPS of -026 beats by 002 SA NewsThu May 12 Kezar Life Sciences Inc. No significant news for KZR in the past two years.

The next quarterly earnings date for Kezar Life Sciences is scheduled on August 12 2022. 22 hours agoWe price the stock at 13 per share and are seeking 38 return objective to this level. Get the latest Kezar Life Sciences stock price and detailed information including KZR news historical charts and realtime prices.

View Kezar Life Sciences Inc KZR investment stock information. SEC Filing - Quarterly Report 10-Q May 12 2022 SEC FilingsThu May 12 ArcelorMittal SA. Kezar Life Sciences market cap is 441 m.

Stock analysis for Kezar Life Sciences Inc KZRNASDAQ GS including stock price stock chart company news key statistics fundamentals and company profile. We estimate the return period of this mispricing to last. Kezar Life Sciences Inc.

News Kezar Life Sciences Inc. Utilizing the teams deep scientific expertise Kezar is developing novel first-in-class small molecule approaches for targeting select proteins to regulate cellular function. KZR shares are trading higher by 50 at 1608 after HC Wainwright.

Kezar Life Sciences Funding Financials Valuation Investors